By SPC News Staff
The FDA approved ustekinumab-auub (Wezlana, Amgen) as an interchangeable biosimilar to Stelara (ustekinumab, Janssen Biotech) for multiple inflammatory diseases.
An interchangeable designation means the biosimilar may be substituted for the reference product without consulting the prescriber. The substitution may occur at the pharmacy, subject to state pharmacy laws that vary by state—similar to how generic drugs are substituted for brand-name drugs.